ES2229928B1 - Nuevos derivados de pirimidin-2-amina. - Google Patents

Nuevos derivados de pirimidin-2-amina.

Info

Publication number
ES2229928B1
ES2229928B1 ES200302275A ES200302275A ES2229928B1 ES 2229928 B1 ES2229928 B1 ES 2229928B1 ES 200302275 A ES200302275 A ES 200302275A ES 200302275 A ES200302275 A ES 200302275A ES 2229928 B1 ES2229928 B1 ES 2229928B1
Authority
ES
Spain
Prior art keywords
optionally substituted
linear
branched
group
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200302275A
Other languages
English (en)
Spanish (es)
Other versions
ES2229928A1 (es
Inventor
Bernat Vidal Juan
Cristina Esteve Trias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to ES200302275A priority Critical patent/ES2229928B1/es
Priority to UY28529A priority patent/UY28529A1/es
Priority to JP2006530007A priority patent/JP2007507443A/ja
Priority to CNA2004800346926A priority patent/CN1886402A/zh
Priority to CA002540765A priority patent/CA2540765A1/en
Priority to ZA200602139A priority patent/ZA200602139B/en
Priority to RU2006114746/04A priority patent/RU2006114746A/ru
Priority to EP04765506A priority patent/EP1668000A1/en
Priority to BRPI0415324-3A priority patent/BRPI0415324A/pt
Priority to UAA200604615A priority patent/UA82563C2/uk
Priority to SG200809684-4A priority patent/SG149077A1/en
Priority to MXPA06003525A priority patent/MXPA06003525A/es
Priority to US10/574,101 priority patent/US20070265273A1/en
Priority to PCT/EP2004/010644 priority patent/WO2005040155A1/en
Priority to AU2004283800A priority patent/AU2004283800B8/en
Priority to KR1020067006384A priority patent/KR20060097010A/ko
Priority to NZ546266A priority patent/NZ546266A/en
Priority to PE2004000948A priority patent/PE20050473A1/es
Priority to TW093129574A priority patent/TW200526645A/zh
Priority to ARP040103547A priority patent/AR046170A1/es
Publication of ES2229928A1 publication Critical patent/ES2229928A1/es
Priority to EC2006006426A priority patent/ECSP066426A/es
Priority to CO06032147A priority patent/CO5690593A2/es
Priority to IL174771A priority patent/IL174771A0/en
Priority to NO20061952A priority patent/NO20061952L/no
Application granted granted Critical
Publication of ES2229928B1 publication Critical patent/ES2229928B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES200302275A 2003-10-02 2003-10-02 Nuevos derivados de pirimidin-2-amina. Expired - Fee Related ES2229928B1 (es)

Priority Applications (24)

Application Number Priority Date Filing Date Title
ES200302275A ES2229928B1 (es) 2003-10-02 2003-10-02 Nuevos derivados de pirimidin-2-amina.
UY28529A UY28529A1 (es) 2003-10-02 2004-09-21 Nuevos derivados de pirimidin-2-amina
KR1020067006384A KR20060097010A (ko) 2003-10-02 2004-09-22 피리미딘-2-아민 유도체 및 이들의 ａ2ｂ 아데노신 수용체길항제로서의 용도
CA002540765A CA2540765A1 (en) 2003-10-02 2004-09-22 Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists
ZA200602139A ZA200602139B (en) 2003-10-02 2004-09-22 Pyrimidin-2-amine derivatives and their use as A2B adenosine receptor antagonists
RU2006114746/04A RU2006114746A (ru) 2003-10-02 2004-09-22 Производные пиримидин-2-амина и их применение в качестве антагонистов аденозинового рецептора а2в
EP04765506A EP1668000A1 (en) 2003-10-02 2004-09-22 Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists
BRPI0415324-3A BRPI0415324A (pt) 2003-10-02 2004-09-22 composto, processo para a produção de um composto, composição farmacêutica, uso de um composto e método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de melhora por antagonismo de receptor de adenosina a2b
UAA200604615A UA82563C2 (uk) 2003-10-02 2004-09-22 Похідні піримідин-2-аміну і їх застосування як антагоністів аденозинового рецептора a2b
SG200809684-4A SG149077A1 (en) 2003-10-02 2004-09-22 Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists
MXPA06003525A MXPA06003525A (es) 2003-10-02 2004-09-22 Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a2b.
US10/574,101 US20070265273A1 (en) 2003-10-02 2004-09-22 Pyrimidin-2-Amine Derivatives and Their Use as A2b Adenosine Receptor Antagonists
JP2006530007A JP2007507443A (ja) 2003-10-02 2004-09-22 ピリミジン−２−アミン誘導体およびａ２ｂアデノシン受容体アンタゴニストとしてのその使用
AU2004283800A AU2004283800B8 (en) 2003-10-02 2004-09-22 Pyrimidin-2-amine derivates and their use as A2B adenosine receptor antagonists
CNA2004800346926A CN1886402A (zh) 2003-10-02 2004-09-22 嘧啶－2－胺衍生物及其作为a2b腺苷受体拮抗剂的用途
NZ546266A NZ546266A (en) 2003-10-02 2004-09-22 Pyrimidin-2-amine derivatives and their use as A2B adenosine receptor antagonists
PCT/EP2004/010644 WO2005040155A1 (en) 2003-10-02 2004-09-22 Pyrimidin-2-amine derivates and their use as a2b adenosine receptor antagonists
PE2004000948A PE20050473A1 (es) 2003-10-02 2004-09-28 Nuevos derivados de pirimidin-2-amina
TW093129574A TW200526645A (en) 2003-10-02 2004-09-30 New pyrimidin-2-amine derivatives
ARP040103547A AR046170A1 (es) 2003-10-02 2004-09-30 Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b
EC2006006426A ECSP066426A (es) 2003-10-02 2006-03-16 Nuevos derivados de pirimidin-2-amina
CO06032147A CO5690593A2 (es) 2003-10-02 2006-03-31 Nuevos derivados de pirimidin 2-amina
IL174771A IL174771A0 (en) 2003-10-02 2006-04-03 Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists
NO20061952A NO20061952L (no) 2003-10-02 2006-05-02 Pyrimidin-2-aminderivater og deres anvendelse som A2B-adenosinreseptorantagonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302275A ES2229928B1 (es) 2003-10-02 2003-10-02 Nuevos derivados de pirimidin-2-amina.

Publications (2)

Publication Number Publication Date
ES2229928A1 ES2229928A1 (es) 2005-04-16
ES2229928B1 true ES2229928B1 (es) 2006-07-01

Family

ID=34507890

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200302275A Expired - Fee Related ES2229928B1 (es) 2003-10-02 2003-10-02 Nuevos derivados de pirimidin-2-amina.

Country Status (24)

Country Link
US (1) US20070265273A1 (enExample)
EP (1) EP1668000A1 (enExample)
JP (1) JP2007507443A (enExample)
KR (1) KR20060097010A (enExample)
CN (1) CN1886402A (enExample)
AR (1) AR046170A1 (enExample)
AU (1) AU2004283800B8 (enExample)
BR (1) BRPI0415324A (enExample)
CA (1) CA2540765A1 (enExample)
CO (1) CO5690593A2 (enExample)
EC (1) ECSP066426A (enExample)
ES (1) ES2229928B1 (enExample)
IL (1) IL174771A0 (enExample)
MX (1) MXPA06003525A (enExample)
NO (1) NO20061952L (enExample)
NZ (1) NZ546266A (enExample)
PE (1) PE20050473A1 (enExample)
RU (1) RU2006114746A (enExample)
SG (1) SG149077A1 (enExample)
TW (1) TW200526645A (enExample)
UA (1) UA82563C2 (enExample)
UY (1) UY28529A1 (enExample)
WO (1) WO2005040155A1 (enExample)
ZA (1) ZA200602139B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159627A1 (en) 2004-10-15 2006-07-20 Dewan Zeng Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
DE102006046410A1 (de) * 2006-09-20 2008-03-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von ischämischen Krankheiten
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CA2685588A1 (en) * 2007-06-08 2008-12-11 Bayer Cropscience Sa Fungicide heterocyclyl-pyrimidinyl-amino derivatives
EP2173722B1 (en) * 2007-07-26 2012-08-29 Novartis AG Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
MX2010002004A (es) 2007-08-22 2010-03-11 Irm Llc Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa.
WO2009026204A1 (en) * 2007-08-22 2009-02-26 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
US8809525B2 (en) * 2010-02-05 2014-08-19 Heptares Therapeutics Limited 1,2,4-triazine-4-amine derivatives
EA201390917A1 (ru) 2010-12-21 2013-12-30 Новартис Аг Дигетероарильные соединения в качестве ингибиторов vps34
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
CN111825698B (zh) 2019-07-30 2021-10-15 杭州阿诺生物医药科技有限公司 腺苷受体拮抗剂
CN112574214B (zh) 2019-07-30 2021-09-28 杭州阿诺生物医药科技有限公司 腺苷受体拮抗剂的制备方法
CN115477653B (zh) * 2022-10-11 2024-04-09 安徽省庆云医药股份有限公司 一种曲拉西利关键中间体及曲拉西利的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763448A (en) * 1993-05-10 1998-06-09 Merck, Sharp & Dohme Limited Pyrmidine derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176399A (en) * 1876-04-18 Improvement in boxes for packing crackers
US22106A (en) * 1858-11-23 Truss-bridge
US275038A (en) * 1883-04-03 Ors to themselves
US23763A (en) * 1859-04-26 Method of adjusting the knives of rotary cutter-heads for planing wood
US42891A (en) * 1864-05-24 Improvement in water-engines
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
IL152023A0 (en) * 2000-04-26 2003-04-10 Eisai Co Ltd Compounds having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same
US6641549B2 (en) * 2001-02-05 2003-11-04 Bsn Medical, Inc. Custom-moldable support for patellar tendinitis
TWI330183B (enExample) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US20050043315A1 (en) * 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763448A (en) * 1993-05-10 1998-06-09 Merck, Sharp & Dohme Limited Pyrmidine derivatives

Also Published As

Publication number Publication date
CO5690593A2 (es) 2006-10-31
AU2004283800B8 (en) 2009-06-18
CA2540765A1 (en) 2005-05-06
NZ546266A (en) 2008-10-31
EP1668000A1 (en) 2006-06-14
ES2229928A1 (es) 2005-04-16
ECSP066426A (es) 2006-10-17
PE20050473A1 (es) 2005-08-24
AU2004283800B2 (en) 2009-05-07
RU2006114746A (ru) 2007-11-20
JP2007507443A (ja) 2007-03-29
AU2004283800A1 (en) 2005-05-06
ZA200602139B (en) 2007-06-27
NO20061952L (no) 2006-06-26
CN1886402A (zh) 2006-12-27
BRPI0415324A (pt) 2006-12-05
UA82563C2 (uk) 2008-04-25
AR046170A1 (es) 2005-11-30
UY28529A1 (es) 2005-04-29
WO2005040155A8 (en) 2006-04-20
TW200526645A (en) 2005-08-16
US20070265273A1 (en) 2007-11-15
WO2005040155A1 (en) 2005-05-06
IL174771A0 (en) 2006-08-20
KR20060097010A (ko) 2006-09-13
MXPA06003525A (es) 2006-06-08
SG149077A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
ES2229928B1 (es) Nuevos derivados de pirimidin-2-amina.
ES2270715B1 (es) Nuevos derivados de pirazina.
ES2241496B1 (es) Nuevos derivados de piridina.
AU2002334205C1 (en) Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
US20230226062A1 (en) Heterocyclic compounds as immunomodulators
CA3150515A1 (en) PRMT5 INHIBITORS IN COOPERATION WITH MTA
ES2778700T3 (es) Nuevos derivados de piperidinilo sustituidos con (hetero)arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
AU2010210018B2 (en) Compounds and compositions as protein kinase inhibitors
US8796284B2 (en) 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists
AU768720B2 (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors
ES2291628T3 (es) Compuestos triciclicos a base de tiofeno y composiciones farmaceuticas que comprenden dichos compuestos.
TWI822713B (zh) 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑
BRPI0722384A2 (pt) compostos inibidores de proteÍna quinase, composiÇÕes contendo os mesmos bem como seus usos
AU2006327876A1 (en) Pyrimidine derivatives
TW201920173A (zh) 作為ｆｇｆｒ抑制劑之雙環雜環
MXPA06014562A (es) Derivados de piridazin-3(2h)-ona y su uso como inhibidores de pde4.
US7906530B2 (en) 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors
CA3147422A1 (en) Inhibitors of cyclin-dependent kinases
ES2297185T3 (es) Nuevos derivados de 4-(pirrolopirimidin-6-il)bencenosulfonamida.
WO2024263957A1 (en) Positive modulators of the muscarinic acetylcholine receptor m4
ES2281251B1 (es) Nuevos derivados de pirido (3',2':4,5) furo (3,2-d) pirimidina.
HK40047614B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
HK40047614A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
BR112017017418B1 (pt) Heterociclos bicíclicos como inibidores de fgfr, seu uso e composição farmacêutica que os compreende

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20050416

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2229928B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180809